Tags

Type your tag names separated by a space and hit enter

Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
Diagn Microbiol Infect Dis. 2011 Apr; 69(4):443-8.DM

Abstract

This antimicrobial resistance surveillance study was performed in 51 medical centers in Japan over an 11-year period. The susceptibilities of 4228 strains including Escherichia coli (491 strains), Klebsiella spp. (462 strains), Enterobacter spp. (459 strains), Citrobacter freundii (358 strains), indole-positive Proteus spp. (386 strains), Serratia spp. (443 strains), Acinetobacter spp. (327 strains), Pseudomonas aeruginosa (473 strains), oxacillin-susceptible Staphylococcus aureus (481 strains), and coagulase-negative staphylococci (CoNS; 348 strains) were tested with 7 β-lactams (cefepime, cefpirome, ceftazidime, cefoperazone/sulbactam, imipenem, and piperacillin for gram-negative bacteria, or oxacillin for gram-positive bacteria). No resistance to these β-lactams (with the exception of ceftazidime) was found in oxacillin-susceptible S. aureus and CoNS. Of the E. coli clinical isolates, 24.6% were resistant to piperacillin, whereas 3.5% or less (cefpirome = 4.5%) were resistant to other β-lactam agents. Klebsiella spp. isolates were more susceptible to imipenem (99.6%), cefepime (98.7%), ceftazidime (98.5%), cefpirome (97.6%), and cefoperazone/sulbactam (97.6%). Isolates of Enterobacter spp., C. freundii, and Serratia spp. were susceptible to imipenem, cefepime, and cefpirome as well. The sensitivities of these organisms against cefepime and cefoperazone/sulbactam were 100%. Acinetobacter spp. isolates were less resistant to cefoperazone/sulbactam (0.6% resistance), imipenem (0.9%), and ceftazidime (2.8%) compared with other β-lactam antibiotics tested. Isolates of P. aeruginosa were more susceptible to piperacillin (9.1% resistance), cefoperazone/sulbactam (9.5%), and cefepime (6.6%) compared with ceftazidime (10.8%), cefpirome (16.3%), and imipenem (23.5%). The proportion of strains resistant to β-lactam antimicrobials has decreased compared with data from 2006 (Diagn. Microbiol. Infect. Dis. 60:177-183), reflecting the reduced consumption of β-lactams in Japan.

Authors+Show Affiliations

Faculty of Medicine, Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo 1438540, Japan. yishii@med.toho-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21396543

Citation

Ishii, Yoshikazu, et al. "Evaluation of Antimicrobial Susceptibility for Β-lactams Against Clinical Isolates From 51 Medical Centers in Japan (2008)." Diagnostic Microbiology and Infectious Disease, vol. 69, no. 4, 2011, pp. 443-8.
Ishii Y, Ueda C, Kouyama Y, et al. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008). Diagn Microbiol Infect Dis. 2011;69(4):443-8.
Ishii, Y., Ueda, C., Kouyama, Y., Tateda, K., & Yamaguchi, K. (2011). Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008). Diagnostic Microbiology and Infectious Disease, 69(4), 443-8. https://doi.org/10.1016/j.diagmicrobio.2010.10.033
Ishii Y, et al. Evaluation of Antimicrobial Susceptibility for Β-lactams Against Clinical Isolates From 51 Medical Centers in Japan (2008). Diagn Microbiol Infect Dis. 2011;69(4):443-8. PubMed PMID: 21396543.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008). AU - Ishii,Yoshikazu, AU - Ueda,Chihiro, AU - Kouyama,Yuichi, AU - Tateda,Kazuhiro, AU - Yamaguchi,Keizo, PY - 2010/08/03/received PY - 2010/10/25/revised PY - 2010/10/31/accepted PY - 2011/3/15/entrez PY - 2011/3/15/pubmed PY - 2011/7/2/medline SP - 443 EP - 8 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 69 IS - 4 N2 - This antimicrobial resistance surveillance study was performed in 51 medical centers in Japan over an 11-year period. The susceptibilities of 4228 strains including Escherichia coli (491 strains), Klebsiella spp. (462 strains), Enterobacter spp. (459 strains), Citrobacter freundii (358 strains), indole-positive Proteus spp. (386 strains), Serratia spp. (443 strains), Acinetobacter spp. (327 strains), Pseudomonas aeruginosa (473 strains), oxacillin-susceptible Staphylococcus aureus (481 strains), and coagulase-negative staphylococci (CoNS; 348 strains) were tested with 7 β-lactams (cefepime, cefpirome, ceftazidime, cefoperazone/sulbactam, imipenem, and piperacillin for gram-negative bacteria, or oxacillin for gram-positive bacteria). No resistance to these β-lactams (with the exception of ceftazidime) was found in oxacillin-susceptible S. aureus and CoNS. Of the E. coli clinical isolates, 24.6% were resistant to piperacillin, whereas 3.5% or less (cefpirome = 4.5%) were resistant to other β-lactam agents. Klebsiella spp. isolates were more susceptible to imipenem (99.6%), cefepime (98.7%), ceftazidime (98.5%), cefpirome (97.6%), and cefoperazone/sulbactam (97.6%). Isolates of Enterobacter spp., C. freundii, and Serratia spp. were susceptible to imipenem, cefepime, and cefpirome as well. The sensitivities of these organisms against cefepime and cefoperazone/sulbactam were 100%. Acinetobacter spp. isolates were less resistant to cefoperazone/sulbactam (0.6% resistance), imipenem (0.9%), and ceftazidime (2.8%) compared with other β-lactam antibiotics tested. Isolates of P. aeruginosa were more susceptible to piperacillin (9.1% resistance), cefoperazone/sulbactam (9.5%), and cefepime (6.6%) compared with ceftazidime (10.8%), cefpirome (16.3%), and imipenem (23.5%). The proportion of strains resistant to β-lactam antimicrobials has decreased compared with data from 2006 (Diagn. Microbiol. Infect. Dis. 60:177-183), reflecting the reduced consumption of β-lactams in Japan. SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/21396543/Evaluation_of_antimicrobial_susceptibility_for_β_lactams_against_clinical_isolates_from_51_medical_centers_in_Japan__2008__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(10)00503-1 DB - PRIME DP - Unbound Medicine ER -